BEAT CF is an adaptive clinical trial investigating the optimal management of cystic fibrosis (CF) lung infections. The trial will aim to optimise antibiotic treatment, as well as other treatments routinely offered to patients during an exacerbation including steroid and mucolytic prescription, and chest physiotherapy.
AusVaxSafety is a national project commissioned by the Commonwealth Government to implement real time safety monitoring for routine vaccines. The project monitors the frequency of vaccine reactions reported by parents via text message.
AuTOMATIC is an adaptive clinical trial to determine whether SMS reminders improve the timeliness of routine vaccination, and if so what is the optimal content and timing of such messages.
CRIPTIC aims to enhance the capacity for novel trials by building interactive patient registries (databases), a statistical and research support network, and an educational hub for adaptive trials.
FeBRILe3 aims to monitor the safety of early discharge (before 48 hours) of “low-risk” infants with fever who are admitted to hospital. The safety of early discharge will be assessed by active monitoring of unplanned hospital readmission rates, other complications, and serious bacterial infections.
IMPACT CF aims to determine which health outcomes are most important to people with cystic fibrosis and their families. The project involves a series of workshops and a discrete choice experiment survey in order to prioritise and select outcomes that may be used in future clinical research.
NICE-GUT is a randomised controlled trial, which aims to assess the impact of oral nitazoxanide (an antimicrobial) on the duration of symptoms among young Aboriginal children admitted to hospital with gastroenteritis.
OPTIMUM is a randomised controlled trial that aims to assess the acceptability of reintroducing one dose of the whole cell pertussis (whooping cough) vaccine into the child immunisation schedule, and to assess whether this reduces the development of food and other allergies.
ORVAC is an adaptive clinical trial assessing the likely impact of an additional rotavirus vaccine dose between 6 to 12 months of age on the burden of diarrhoeal disease in remote Australian Indigenous children.
The PEA study aims to evaluate the use of a decision-making tool for supporting antibiotic selection in children with suspected urine infections. Use of the tool is expected to improve prescribing and aims to slow the emergence of antibiotic resistance.
PLATINUM C is an adaptive clinical trial which aims to help in the elimination of hepatitis C by evaluating novel ways of delivering antiviral medication and other interventions.